Cardiff Oncology (XE7C) Price & Analysis

3 Followers

XE7C Stock Chart & Stats

€0.67

€0.04(6.67%)

At close: Jul 24 4:00 PM EDT

€0.67

€0.04(6.67%)

Day’s Range― - ―

52-Week Range€0.60 - €2.67

Previous CloseN/A

Volume0.00

Average Volume (3M)254.00

Market Cap

€65.71M

Enterprise Value€54.85

Total Cash (Recent Filing)€34.52M

Total Debt (Recent Filing)€457.00K

Price to Earnings (P/E)―

Beta1.85

Next Earnings

Oct 29, 2026

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.60

Shares Outstanding77,795,250

10 Day Avg. Volume400

30 Day Avg. Volume254

Financial Highlights & Ratios

PEG Ratio0.15

Price to Book (P/B)4.14

Price to Sales (P/S)316.73

P/FCF Ratio-4.95

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€3.43

Price Target Upside412.13% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering6

EPS Forecast (FY)-0.52

Revenue Forecast (FY)€219.79K

Bulls Say, Bears Say

Bulls Say

Phase 2 Efficacy And Registrational PathThe interim Phase 2 signal provides clinical validation for onvansertib in first-line RAS-mutated colorectal cancer. A defined Phase 3 and regulatory pathway could materially improve partnering, approval, and future commercialization prospects.

Very Low LeverageMinimal debt reduces solvency pressure and interest obligations while Cardiff advances its pipeline. This gives the company greater financial flexibility than a highly leveraged biotech, although it does not eliminate the need for future equity funding.

Near-term Funding SecuredThe financing extends near-term liquidity and supports continued clinical development without relying immediately on debt. Institutional and insider participation may also help sustain execution, though the shares and warrants increase potential dilution.

Bears Say

Persistent Cash BurnLarge recurring cash outflows mean Cardiff cannot currently self-fund research and clinical operations. Continued development therefore depends on additional capital, licensing proceeds, or partnerships, creating financing and execution risk over the next several quarters.

Pre-commercial Loss ProfileCardiff lacks a meaningful commercial revenue base to offset substantial R&D and operating costs. Until a candidate is approved and launched or partnered, sustained losses will constrain financial resilience and may erode shareholder value through repeated funding needs.

Onvansertib License And IP UncertaintyThe dispute could affect Cardiff’s rights to key intellectual property and its ability to advance or commercialize the lead asset. Prolonged litigation may consume resources, delay development, or weaken negotiating leverage with potential partners.

Cardiff Oncology News

Cardiff Oncology reports Q2 EPS (14c), consensus (16c)

Reports Q2 revenue $104,000, consensus $62,780. “The second quarter was an important period of progress for Cardiff, highlighted...

11d ago

CRDF

Cardiff Oncology downgraded to Market Perform from Outperform at William Blair

William Blair downgraded Cardiff Oncology (CRDF) to Market Perform from Outperform. Post-Q2 results, the firm said the company’s...

11d ago

CRDF

Okta upgraded, Gap downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

11d ago

BSP

GAP

Take-Two, Quantum, On, Cardiff, Autodesk Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($TTWO) ), ( ($QMCO) ), ( ($ONON) ), ( ($CRDF)...

13d ago

ADSK

CRDF

CRDF Earnings this Week: How Will it Perform?

Cardiff Oncology, Inc. (CRDF) is scheduled to report 2nd quarter earnings on 07/30/2026. Regarding Q2 estimates, Wall Street...

1M ago

CRDF

Cardiff Oncology completes $10 million financing transaction

Cardiff Oncology ( ($CRDF) ) just unveiled an announcement. On July 14, 2026, Cardiff Oncology entered into agreements...

1M ago

CRDF

Cardiff Oncology announces $10M registered direct offering

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. Published first on TheFly...

1M ago

CRDF

Cardiff, Verastem, Fluence, Quantum-Si, Opera Insider Shock

Insiders have been trading these 5 stocks: (($CRDF)), (($VSTM)), (($FLNC)), (($QSI)) and (($OPRA)). Here is a breakdown of...

2M ago

QSI

CRDF

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Amplitech Group Inc (AMPG)...

2M ago

SLS

AMPG

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Ares Capital (ARCC) 30.09%...

2M ago

YSS

ARCC

Cardiff Oncology Shareholders Approve Directors and Equity Plan

Cardiff Oncology ( ($CRDF) ) just unveiled an update. On June 11, 2026, Cardiff Oncology, Inc. held its...

3M ago

CRDF

Campbell, Crescent, Cardiff, Sherwin, Take-Two Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($CPB) ), ( ($CBIO) ), ( ($CRDF) ), ( ($SHW)...

3M ago

CPB

SHW

Cardiff Oncology price target lowered to $4 from $10 at Lucid Capital

Lucid Capital analyst Christopher Liu lowered the firm’s price target on Cardiff Oncology (CRDF) to $4 from $10...

3M ago

CRDF

Andy Hsieh Reaffirms Buy on Cardiff Oncology as Onvansertib Data and Streamlined Phase III Design Strengthen Risk‑Reward Profile

William Blair analyst Andy Hsieh has reiterated their bullish stance on CRDF stock, giving a Buy rating on...

3M ago

CRDF

XE7C FAQ

What was Cardiff Oncology, Inc.’s price range in the past 12 months?

Cardiff Oncology, Inc. lowest stock price was €0.60 and its highest was €2.67 in the past 12 months.

What is Cardiff Oncology, Inc.’s market cap?

Cardiff Oncology, Inc.’s market cap is €65.71M.

When is Cardiff Oncology, Inc.’s upcoming earnings report date?

Cardiff Oncology, Inc.’s upcoming earnings report date is Oct 29, 2026 which is in 62 days.

How were Cardiff Oncology, Inc.’s earnings last quarter?

Cardiff Oncology, Inc. released its earnings results on Aug 11, 2026. The company reported -€0.121 earnings per share for the quarter, missing the consensus estimate of -€0.104 by -€0.017.

Is Cardiff Oncology, Inc. overvalued?

According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cardiff Oncology, Inc. pay dividends?

Cardiff Oncology, Inc. does not currently pay dividends.

What is Cardiff Oncology, Inc.’s EPS estimate?

Cardiff Oncology, Inc.’s EPS estimate is -0.12.

How many shares outstanding does Cardiff Oncology, Inc. have?

Cardiff Oncology, Inc. has 77,795,250 shares outstanding.

What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?

Cardiff Oncology, Inc. reported an EPS of -€0.121 in its last earnings report, missing expectations of -€0.104. Following the earnings report the stock price went down -1.724%.

Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?

Currently, no hedge funds are holding shares in DE:XE7C

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Cardiff Oncology Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-50.71%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cardiff Oncology, Inc.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Cardiff Oncology (XE7C) Earnings & Revenues

Historic Earnings Reports

XE7C Stock 12 Month Forecast

Average Price Target

€3.43

▲(412.13% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"€6","-1":"-€1","0.75":"€0.75","2.5":"€2.5","4.25":"€4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5.146857,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€5.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.431238,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€3.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.715619,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.72</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.662,1.006989,1.351978,1.696967,2.041956,2.386945,2.731934,3.076923,3.421912,3.766901,4.11189,4.456879,4.801868,{"y":5.146857,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.662,0.8750183076923077,1.0880366153846155,1.301054923076923,1.5140732307692308,1.7270915384615386,1.9401098461538462,2.1531281538461537,2.3661464615384618,2.5791647692307693,2.792183076923077,3.0052013846153844,3.2182196923076924,{"y":3.431238,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.662,0.7430476153846154,0.8240952307692307,0.9051428461538462,0.9861904615384616,1.067238076923077,1.1482856923076923,1.2293333076923076,1.310380923076923,1.3914285384615384,1.4724761538461537,1.553523769230769,1.6345713846153846,{"y":1.715619,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.264,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.772,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.664,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.862,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.87,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.425,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.362,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.552,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.322,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.301,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.312,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.056,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.662,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >